CORTISPORIN (hydrocortisone; neomycin sulfate; polymyxin b sulfate) by Monarch Therapeutics is clinical pharmacology colistin sulfate is a polypeptide antibiotic which penetrates into and disrupts the bacterial cell membrane. Approved for superficial bacterial infections of the external auditory canal, caused by organisms susceptible to the action of the antibiotics. First approved in 1975.
Drug data last refreshed 20h ago · AI intelligence enriched 6d ago
CORTISPORIN is a fixed-dose combination otic solution containing hydrocortisone (corticosteroid), neomycin sulfate (aminoglycoside antibiotic), and polymyxin B sulfate (polypeptide antibiotic). It treats superficial bacterial infections of the external auditory canal by combining anti-inflammatory and broad-spectrum bactericidal activity against gram-positive and gram-negative organisms. The corticosteroid reduces inflammation and pruritus while the antibiotics eliminate susceptible bacteria including Staphylococcus aureus and Pseudomonas aeruginosa.
This established generic-equivalent product is approaching loss of exclusivity with moderate competitive pressure (30% intensity), signaling a contracting brand team focused on cost management and retention rather than growth initiatives.
CLINICAL PHARMACOLOGY Colistin sulfate is a polypeptide antibiotic which penetrates into and disrupts the bacterial cell membrane. Neomycin sulfate is an aminoglycoside antibiotic which inhibits protein synthesis, disrupting the normal cycle of ribosomal function. Hydrocortisone acetate is a…
Worked on CORTISPORIN at Monarch Therapeutics? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
CORTISPORIN offers limited career growth opportunity as a mature, generic-equivalent product with zero linked job postings and approaching loss of exclusivity. Roles available are primarily defensive (protecting market share, managing payer relationships, optimizing pricing) rather than growth-oriented, making this product less attractive for professionals seeking innovation-driven or high-visibility career advancement.